Literature DB >> 6254

The treatment of resistant hypertension.

P S Kincaid-Smith.   

Abstract

Resistant hypertension can be defined in terms of lack of blood pressure response to hypotensive agents, but there may be a big difference between standing and lying blood pressure levels. In general target organ damage and papilloedema improve if the standing blood pressure is controlled; however, progression can occasionally be documented when only the supine blood pressure remains uncontrolled. Resistant hypertension was a frequent phenomenon when ganglion blocking agents and hydrallazine were the only effective hypotensive agents. With the advent of the thiazides, effective control of the blood pressure became the exception rather than the rule; however, it was not until the advent of adrenergic blocking agents that reduction of supine blood pressures was regularly achieved. The addition of hydrallazine or prazosin to a combination of a thiazide and beta-adrenoreceptor blocking agent produces a further significant fall in the blood pressure lying and standing. This combination will control the blood pressure in most patients, but a few remain refractory to maximum doses and will require treatment with oral diazoxide or minoxidil. Both these powerful vasodilators are very effective in resistant hypertension. Oral diazoxide permits excellent control and allows a 10-fold reduction in the doses of other agents. Minoxidil usually needs to be combined with moderate doses of beta-blocking agents to reduce the marked reflex tachycardia. Only a 50% reduction in other hypotensive agents was achieved in patients treated with minoxidil and two patients proved resistant to minoxidil, but subsequently responded to oral diazoxide.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 6254     DOI: 10.2165/00003495-197600111-00020

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  10 in total

1.  Results of treatment in malignant hypertension: a seven-year experience in 94 cases.

Authors:  M HARINGTON; P KINCAID-SMITH; J McMICHAEL
Journal:  Br Med J       Date:  1959-11-14

2.  Effect of chlorothiazide on the hypotensive action of mecamylamine and on its urinary excretion.

Authors:  M HARINGTON; P KINCAID-SMITH
Journal:  Lancet       Date:  1958-02-22       Impact factor: 79.321

3.  Changing concepts in the management of hypertension.

Authors:  P Kincaid-Smith; I M Macdonald; A Hua; M C Laver; P Fang
Journal:  Med J Aust       Date:  1975-03-15       Impact factor: 7.738

4.  Double-blind comparison of two beta-blocking drugs with previous therapy in the treatment of hypertension.

Authors:  M C Laver; P Fang; P Kincaid-Smith
Journal:  Med J Aust       Date:  1974-02-09       Impact factor: 7.738

5.  Treatment of essential hypertension with combined vasodilation and beta-adrenergic blockade.

Authors:  R Zacest; E Gilmore; J Koch-Weser
Journal:  N Engl J Med       Date:  1972-03-23       Impact factor: 91.245

6.  Oral diazoxide in uncontrolled malignant hypertension.

Authors:  P Fang; I MacDonald; M Laver; A Hua; P Kincaid-Smith
Journal:  Med J Aust       Date:  1974-10-26       Impact factor: 7.738

7.  Propranolol in the treatment of hypertension.

Authors:  A T Axford; L Gilchrist
Journal:  Br J Clin Pract       Date:  1971-07

8.  A new look at the treatment of severe hypertension.

Authors:  P Kincaid-Smith; P Fang; M C Laver
Journal:  Clin Sci Mol Med Suppl       Date:  1973-08

9.  Treatment of hypertension with propranolol.

Authors:  B N Prichard; P M Gillam
Journal:  Br Med J       Date:  1969-01-04

10.  Potentiating effect of chlorothiazide (diuril) in combination with antihypertensive agents; preliminary report.

Authors:  E FREIS; I M WILSON
Journal:  Med Ann Dist Columbia       Date:  1957-09
  10 in total
  1 in total

Review 1.  Treatment resistant hypertension--investigation and conservative management.

Authors:  Franz Weber; Manfred Anlauf
Journal:  Dtsch Arztebl Int       Date:  2014-06-20       Impact factor: 5.594

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.